מכפיל EV/EBITDA: Organovo Holdings Inc (ONVO)

Organovo Holdings, Inc. (ONVO) leads the creation of living tissues via 3D printing, utilizing the NovoGen system to optimize pharmaceutical research. This price chart on GURU.Markets confirms an EV/EBITDA valuation of . Strict patent restrictions and certification complexities ensure a high barrier to entry. The business is currently in an active development phase, consuming existing capital reserves without a stable operational cash flow.
Organovo Holdings (ONVO) - פילוחי מדדים ודוחות פיננסיים

To identify the sector's fundamental leaders, the analyst compares the enterprise value (EV) of the business with its earnings before interest, taxes, depreciation, and amortization. This ratio assesses the real value of assets relative to the ability to generate cash flow, which is critical for Organovo Holdings, Inc. (ONVO) during its bioprinted tissue development phase. The current value of on the EV/EBITDA chart alongside historical data allows for an assessment of how future licensing deals will impact capitalization.